| 摘要 |
The following are claimed: (1) use of one or more purified polypeptides or glycopeptides derived from the E, preM, NS1, NS3 or NS5 proteins of different flavivirus (especially dengue virus) serotypes in the manufacture of a diagnostic kit for determining the serotype implicated in an infection and the primary or secondary nature of the infection; (2) a diagnostic kit for determining the primary or secondary status of infection by one or more Dengue virus serotypes, comprising (a) one or more polypeptides or glycopeptides as above C-terminally tagged with a sequence of 2-8 amino acids selected from His, Trp and Cys, (b) labelled or modified anti-IgG antibodies, (c) labelled or modified anti-IgM antibodies, and (d) labelled or modified anti-IgA antibodies; (3) a purified flavivirus-specific antigen comprising a labelled polypeptide or glycopeptide derived from the E, preM, NS1, NS3 or NS5 proteins of a flavivirus. |
